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Abstract
Cannabinoids are compounds present in Cannabis sativa (phytocannabinoids), 
endogenously produced (endocannabinoids) or synthesized, that bind to G 
protein-coupled receptors named cannabinoid receptors B1 and B2. They were 
first described as psychotropic compounds; however, cannabinoids are also potent 
immunoregulatory agents. Cannabinoids can modulate neutrophil activity in sterile 
and infectious inflammatory diseases. Concerning sterile inflammatory diseases as 
arthritis, ischemic diseases, and colitis, the use of CB2 agonist impairs the intracel-
lular signaling pathways involved in the production of inflammatory mediators and 
expression of adhesion molecules. As a consequence, neutrophils did not release 
metalloproteinases either to adhere to endothelial cells, resulting in reduced tissue 
damage. A similar anti-inflammatory CB2 agonist mechanism of action in sepsis 
and mycobacterial infection models is observed. However, it is not clear if inflam-
mation resolution promoted by cannabinoid treatment during infection is also 
related to microbial viability. Despite the growing literature showing the effects of 
cannabinoids on neutrophils, there are still some gaps that should be filled before 
proposing cannabinoid-based drugs to treat neutrophil-dependent diseases.
Keywords: cannabinoid agonist, inflammation, infection, endocannabinoids, 
phytocannabinoids, synthetic cannabinoids
1. Introduction
Neutrophils have been classically recognized as the most relevant cell during 
acute inflammatory responses and, more recently, in chronic inflammation [1]. On 
the one hand, neutrophils produce bactericidal molecules and coordinate the accu-
mulation of pro-resolving cells. On the other hand, neutrophil over activation leads 
to tissue damage. In this context, several approaches have been proposed to regulate 
the accumulation and the activity of neutrophils in pathological conditions.
In parallel, the findings concerning the importance of the endocannabinoid 
system as the endogenous immunoregulatory mechanism raise questions on how 
it could be therapeutically used to treat inflammatory diseases. In this chapter, we 
discuss how the endocannabinoid system can be used to modulate the activity of 




Cannabis sativa (marijuana) is one of the oldest plants that produced psychoac-
tive effects on humans. In addition, it has been used in medicine in controlling 
pain, convulsion, inflammation, and asthma [2, 3]. Cannabinoids are a group of 
lipophilic and pharmacologically active compounds present in C. sativa. The first 
component from cannabis identified was the tetrahydrocannabinol (Δ9-THC) and 
and, as other cannabinoids, binds to G protein-coupled receptors (GPCRs) named 
cannabinoid receptors [4, 5].
Cannabinoid receptor agonists are responsible for several biological effects, such 
as analgesic, antiemetic, antitumor, and anti-inflammatory [6–13], and are classi-
fied into three groups based on their origin: endogenous cannabinoids (endocan-
nabinoids—Figure 1a and b), phytocannabinoids (Figure 1c and d), and synthetic 
cannabinoids (Figure 1e and f) [5].
Endocannabinoids (eCBs) are eicosanoids derived from polyunsaturated chain 
fatty acids, such as arachidonic acid, and comprise amides, esters, and ether [14]. 
Anandamide (AEA) was the first endocannabinoid described in the mammalian 
Figure 1. 
Chemical structure of some representatives of the cannabinoid agonists. (a) 2-AG, (b) AEA, (c) cannabidiol, 
(d) β-caryophyllene, (e) JWH-133, and (f) WIN 55212-2.
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brain and other tissues [15], followed by 2-arachidonoylglycerol (2-AG) [16, 17]. 
The AEA and 2-AG represent the major substances of this class. The eCBs together 
with the cannabinoid receptors and the enzymes that regulate their biosynthesis 
and degradation constitute the “endocannabinoid system” [18]. Beyond the well-
known psychotropic effects, the endocannabinoid system plays an essential immu-
nomodulatory role by modulating the release of cytokines and on acute or chronical 
diseases through two main ways, neuro- and immunomodulation [19, 20].
The group of phytocannabinoids consists of active substances initially extracted 
from Cannabis sativa, whose pharmacological activity is associated with the terpene 
phenolic class. Phytocannabinoids are classified into two groups: psychoactive 
cannabinoids, such as Δ9-THC, and non-psychoactive such as cannabidiol and 
cannabinol [21, 22]. More recently, other molecules have been isolated from dif-
ferent plant species, which exert effects through cannabinoid receptors, such as 
the alkylamides derived from Echinacea angustifolia and Otanthus maritimus and 
sesquiterpene, as β-caryophyllene, found in some plant species from Copaifera 
genus [23–27].
The characterization of the chemical structure of Δ9-THC and endocan-
nabinoids allowed the development of synthetic cannabinoids. From THC, it was 
possible to synthesize several compounds that have similar chemical structures with 
different levels of affinity for cannabinoid receptors [5, 28]. Synthetic cannabinoids 
have been used as a pharmacological tool for in vivo or in vitro studies to explore 
the therapeutic potential of the cannabinoid system. However, it has already been 
described that metabolites form dipyrone and paracetamol exert its analgesic effects 
by inhibiting endocannabinoid biosynthesis and binding of cannabinoid receptors, 
respectively [29].
The cannabinoid receptors CB1 and CB2 are the main receptors of the cannabi-
noid system. Both belong to the family of GPCRs, specifically inhibitory G protein 
(Gi) [30]. The binding of agonists to cannabinoid receptors inhibits adenylate 
cyclase (AC) and modulates activation of different members of the MAPK family, 
including ERK1/ERK2, p38, and JNK1/2 (Figure 2) [30–37]. By inhibiting AC, the 
reduction of the second messenger cyclic adenosine monophosphate (cAMP) leads 
to the opening of rectifying potassium channels. CB1 also mediates the inhibition of 
N-type and P/Q-type calcium currents [22, 38]. Besides CB1 and CB2, the existence 
of a third cannabinoid receptor (CB3) has been suggested [39], and there are two 
orphan G protein-coupled receptors (GPCRs) which overlap with CB1 and CB2, 
named GPR18 and GPR55 [40]. In addition to activation via GPCRs, cannabinoids 
can perform their actions by activating PPARs, including PPARγ [41–43].
CB1 is expressed in the central nervous system, especially by neurons [44] and 
modulates physiological processes, such as motor behavior, learning, memory and 
cognition, and pain perception [45]. This receptor is associated with the psychotro-
pic effects of cannabinoid agonists, such as THC [46, 47].
CB2 is the peripheral receptor for cannabinoid agonists. It is mainly expressed 
in immune tissues such as the spleen and thymus as well as in blood cell subpopula-
tions such as CD4 and CD8 lymphocytes, neutrophils, monocytes, natural killer 
(NK) cells, and B lymphocytes [47]. Nevertheless, CB2 is also found at low levels in 
neuronal and nonneuronal cells of the brain, but it does not produce psychoactive 
effects [47–49].
The CB2 expression intensity in immune cells depends on cell populations and 
activation state [50, 51]. Macrophages from different tissues increase CB2 expres-
sion after stimulation with interferon (IFN)-γ, which suggests that macrophages 
activated during an inflammatory process are more sensitive to the action of can-
nabinoid agonists than those in the resting state [52]. The first evidence that can-
nabinoids might modulate cytokine production was in the mid-1980s when murine 
Neutrophils
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cells treated with agonist cannabinoid reduced the levels of type I interferons (IFN-α 
and IFN-β) after stimulation with LPS or polyinosinic-polycytidylic acid (polyI:C). 
Many subsequent studies have shown that cannabinoids inhibited the production of 
cytokines in innate and adaptive immune responses, both in animal models and in 
human cell cultures (to review [53]). In such a way, CB2 has become an important 
target, especially in inflammatory conditions. The CB2 receptor modulates immune 
cell functions, both in vitro and in animal models of inflammatory diseases. In this 
context, some studies have reported that mice lacking the CB2 receptor have an 
exacerbated inflammatory phenotype (to review [19]). Besides, CB2 agonists have an 
inhibitory effect on leukocyte migration and in the production of pro-inflammatory 
mediators in vivo and in vitro, showing a high anti-inflammatory potential [54]. 
Due to the lack of psychotropic effects, CB2 agonists are considered a promising 
therapeutic strategy for the treatment of chronic inflammatory diseases. Preclinical 
studies showed the action of CB2 agonists on different experimental models of 
inflammation, such as colitis, arthritis, cerebral ischemia, and sepsis [10, 53, 55–59], 
and in these studies, they showed that the action of CB2 agonists modulated the 
neutrophil activity.
3. Neutrophils, cannabinoid system, inflammation, and infection
3.1 Neutrophils and cannabinoid system
Neutrophils play a crucial role in inflammatory processes, which are present in 
the pathology of different diseases. The neutrophil recruitment to the inflammatory 
site is an essential stage in the inflammatory responses; these cells are released from 
Figure 2. 
Neutrophil activated expresses cannabinoid receptors (CB receptors). The cannabinoid receptors CB1 and CB2 
belong to the family of GPCRs, specifically inhibitory G protein (Gi/0). The binding of agonists to cannabinoid 
receptors inhibits the activation of different members of the MAPK family (ERK1/2, p38, and JNK1/2), gene 
expression, as well as reduces cyclic adenosine monophosphate (cAMP) levels by inhibiting adenylate cyclase 
(AC) activity.
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the bone marrow to the periphery immediately after the first signal of inflamma-
tion. The mobilization of neutrophils from the bone marrow is conducted by the 
hematopoietic cytokine granulocyte colony-stimulating factor (G-CSF), which 
mobilizes neutrophils indirectly by shifting the balance between ligands to CXCR4 
(CXCL12) and CXCR2 (CXCL1 and CXCL2) [60]. Neutrophil-active chemoattrac-
tant, as chemokines CXCL1 and CXCL2, is produced and released within the bone 
marrow and in inflamed tissue. In this context, chemokines from inflamed foci 
might make their way to the bone marrow and modulate neutrophil egress. Thus, 
CXCL1 and CXCL2 can act locally by inducing neutrophil recruitment from blood 
to peripheral tissue and systemically by inducing neutrophil mobilization from the 
bone marrow to the bloodstream [61].
Once in the peripheral blood, neutrophils can be rapidly recruited into inflamed or 
infected tissues. A panel of diverse stimuli, especially pathogen-associated molecular 
patterns (PAMPs) and damage-associated molecular patterns (DAMPs), activates 
macrophages, mast cells, or stromal cells to produce and release pro-inflammatory 
mediators as interleukin (IL)-1β, tumor necrosis factor (TNF), CXCL8, CXCL1, 
CXCL2, and lipid mediators, such as leukotriene B4 (LTB4) and endocannabinoids 
[61, 62]. In inflammatory loci, neutrophils find antigen, molecules, and/or immune 
complexes that trigger different actions, such as phagocytosis, production of reactive 
oxygen species (ROS), and release of enzyme-rich granules (as collagenases, gelati-
nases, neutrophil myeloperoxidase (MPO), and elastase [63]). Neutrophils enter the 
tissue through surface molecules which interact with vascular endothelial cells. This 
process is accompanied by a regulated rearrangement of the cytoskeleton of neutro-
phils that lead to actin polymerization [64], which is mainly governed by members of 
the Rho family GTPases including RhoA, Rac1, and Cdc42 [65].
Concerning cannabinoid receptor expression, it was observed that neutrophil 
from healthy donors expresses low levels of CB2 [66]. In addition, it was shown that 
the CB2 receptor plays a crucial role in neutrophil differentiation, and it has been 
implicated in the development of leukemia [67, 68].
The role of the cannabinoid system in neutrophil migration is controversial. The 
activation of CB2 receptors by 2-AG did not induce polarization and migration of 
human blood neutrophils [69]. However, pretreatment of neutrophils with 2-AG 
inhibited the fMLP- and CXCL8-induced migration without affecting the polariza-
tion of the cells [69]. In contrast, McHugh and coworkers showed that 2-AG does 
not inhibit the migration of human neutrophils toward fMLP and does not show 
chemotactic effects by itself [70]. Furthermore, Balenga and coworkers showed that 
2-AG induces migration of neutrophils toward inflammatory sites, through cross 
talk with activated GPR55 [62].
Despite the uncertainty regarding the involvement of CB2 agonist with the 
neutrophil migration and action, some studies show that there is a relationship 
between neutrophils and cannabinoid system in the pathogenesis of inflammatory 
or infection diseases (Table 1). In the next section, we will discuss the cannabinoid 
system and its action on the neutrophil participation in inflammatory and infection 
conditions [54, 62, 69–85].
3.2 Neutrophils, cannabinoid system, and inflammation
The action of CB2 agonists on their receptors impairs the secretion of pro-
inflammatory cytokines and chemokines and reduces the recruitment of neutro-
phils. As discussed previously, neutrophils play a significant role in inflammatory 
diseases, including acute, chronic, autoimmune, infectious, and noninfectious 
conditions. The relation between neutrophil and cannabinoid system in inflamma-
tory disease was discussed in this section.
Neutrophils
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Increased macro- and microscopic colon damage scores, a high number of 
macrophage and neutrophil and MPO activity, characterizes experimental colitis. 
The activation of CB receptors by their ligands produces a protective effect in 
experimental colitis by decreasing prostaglandin, ROS and nitric oxide production, 
and reduction of leukocyte accumulation as neutrophils, resulting in diminished 
of colon tissue inflammation. Besides, mice lacking functional CB receptors are 
less resistant to colon inflammation than wild-type animals [53, 86]. The synthetic 
non-psychotropic cannabinoids as JWH-133, cannabinoid from the plant as canna-
bigerol [87] and β-caryophyllene [54], and synthetic atypical cannabinoid O-1602 
(non-CB1 and CB2 ligands) [88] have been able to inhibit neutrophil recruitment in 
colitis models. Thus, during inflammation, the CB2 receptor activation by endocan-
nabinoids or synthetic cannabinoid provides a mechanism for the reestablishment 
of regular GI transit (to review [89]).
Neutrophils are also essential cells in the development of arthritis. Neutrophils 
are abundant in inflamed joints, and these cells are essential to the initiation and 
progression of rheumatoid arthritis (RA). Neutrophil effector mechanisms include 
the release of pro-inflammatory cytokines, reactive oxygen and nitrogen species 
Table 1. 
Cannabinoid agonists, which exert action on neutrophils.
7Cannabinoid Receptors as Regulators of Neutrophil Activity in Inflammatory Diseases
DOI: http://dx.doi.org/10.5772/intechopen.81995
(ROS and RNS), and granules containing derivative enzymes, which can cause 
further damage to the tissue and amplify the inflammatory response [90]. In such 
way, it has already been described that in RA there is an increase of CB2 expression 
and elevated endocannabinoid levels, observed in the synovial tissue and fluid 
from a patient with this disease [91]. Synovial fibroblasts and macrophages are 
mainly responsible for endocannabinoid production. These cells also are essential 
in the production of chemokines (CXCR1 or 2 ligands, such as CXCL8), the C5a 
fragment of the complement system, and LTB4 which are responsible for neutro-
phil mobilization to the synovial cavity [61]. In this context, the activation of CB2 
receptors inhibits the production of pro-inflammatory mediators, like chemokines, 
which reduces the leukocyte migration, like neutrophils, to the synovial cavity and 
metalloproteinase release [92]. Moreover, the activation of CB2 receptors inhibits 
IL-1β-induced activation of extracellular signal-regulated kinases 1 and 2 and p38 
mitogen-activated protein kinase in RA fibroblast [92].
The role of cannabinoid in neutrophils was also studied in ischemic models. 
Endocannabinoids act via the CB2 receptor in the modulation of the inflamma-
tory response and myocardial remodeling after infarction. CB2 receptor plays an 
essential role in the formation of infarction border zone, collagen deposition, and 
organization of stable scar during remodeling. Duerr and coworkers [93] showed 
increased numbers of neutrophils in the heart ischemic area of CB2 receptor-
deficient (Cnr2−/−) mice when compared with healthy mice. These results suggest 
that CB2 receptor modulates neutrophil migration to inflammatory infarction 
site [93]. In accordance, activation of the cannabinoid CB2 receptor by JWH-133 
protects against atherosclerotic plaque formation and may also decrease neutro-
phil MMP-9 release, which reduces the vulnerability of ischemic stroke plaque 
in arteries. Together, the studies suggest that CB2 agonists represent a promising 
anti-atherosclerotic treatment [84].
Even though CB1 is the most prominent receptor in the CNS, CB2 modulates 
neuroinflammation. CB2 activation by JWH-133 reduced the number of neutrophils 
in the ischemic brain. Furthermore, CB2 activation in vitro inhibits adherence of 
neutrophils to brain endothelial cells. JWH-133 also interfered with the migration 
of neutrophils induced by the endogenous chemokine CXCL2 through activation 
of the MAP kinase p38. This effect on neutrophils is probably responsible for the 
neuroprotection mediated by JWH-133 [56].
3.3 Neutrophils, cannabinoid system, and infection
The relation between neutrophil and infection is well established [94]. On one 
hand, the exacerbation of neutrophil activation could lead to tissue damage. On 
the other hand, neutrophils control microorganism growth. In this context, it is 
essential to study the effect of cannabinoids on neutrophils during infections and 
evaluate if and how the cannabinoid system modulates neutrophil activity.
The interest in the relationship among cannabinoids and infections exists since 
the 1960s when studies regarding “hippie subculture” observed the increase of sexu-
ally transmitted infections by marijuana consumers [95]. By this time, the studies 
focused on consumer behavior and how it could increase susceptibility to infections 
but did not evaluate the effect of cannabinoids on host response to infections [96]. 
Nowadays, it is known that endocannabinoid system regulates and is regulated by 
host microbiota, a balance that protects the host from the infection-triggered inflam-
matory response [29]. However, the increase of studies showing the immunoregula-
tory role of the endocannabinoid system raises questions about if cannabinoids 
could modulate microbial viability and/or neutrophil response during infections.
Neutrophils
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Studies concerning the modulation of neutrophil activity by cannabinoids 
during infections are mostly addressed to experimental bacterial infection as sepsis 
model. Neutrophil activity during experimental sepsis is well characterized in 
studies in vivo (to review [97–99]). By using LPS sepsis model, Smith and coworkers 
showed that treatment with cannabinoid receptor agonists reduced the migration 
of neutrophils in the peritoneal cavity by inhibiting neutrophil chemoattractant 
production [59]. The authors conclude that CB2 was responsible for impairing neu-
trophil migration. In accordance, studies performed in CB2-deficient mice submit-
ted to sepsis induced by cecal ligation and puncture showed increased production 
of neutrophil chemotactic chemokines and increased numbers of neutrophil in 
the bone marrow and lung tissue. Interestingly, despite the increase in neutrophil 
numbers, neutrophils from CB2-deficient mice were not able to activate the MAPK 
pathway neither control bacterial load [57, 100]. Furthermore, in mycobacteria 
model of infection, it was observed that CB2 agonism impairs neutrophil adhesion 
to endothelial cells probably by inhibiting actin polymerization [83].
There are few and controverting data concerning CB1 effects on neutrophils 
during infection. Leite-Avalca and coworkers showed that CB1 antagonist given to 
mice submitted to CLP increased the survival rate but not change neutrophil accu-
mulation in the peritoneal cavity [101]. Nevertheless, Kianian and coworkers showed 
that antagonism of CB1 reduced the adhesion of leukocytes to intestinal submucosal 
venules [102]. It is noteworthy that in the sepsis model, the activation of CB1 increases 
the systemic arterial pressure and the flow and decreases the arterial oxygenation; 
however, it decreases the inflammatory cytokine production [103, 104]. In such a way, 
an indirect effect of CB1 on leukocyte behavior during sepsis cannot be ruled out.
The results regarding the immunomodulatory effects of cannabinoids in infec-
tion are in accordance with the host-directed therapy approach that aims to activate 
protective responses against microbes in addition to antimicrobial therapy [105]. 
However, it should be mentioned that antibiotics perturb gut microflora, which 
could result in the endocannabinoid system unbalance and, thus, in neuropsychi-
atric disorders [29]. Indeed, further studies are necessary to propose to activate the 
endocannabinoid system, especially the CB2 pathway, during infections.
4. Conclusion
An increasing amount of data concerning the immunoregulatory role of canna-
binoids, especially the CB2 agonists, has been raising the interest in developing new 
therapeutic strategies for inflammatory diseases. It is already known that the mech-
anism of action of well-established anti-inflammatory drugs, like paracetamol, 
depends on the activation of the endocannabinoid system [29]. However, despite 
all studies showing that cannabinoids can modulate neutrophil biology, there is a 
long way to go to achieve cannabinoid-based drugs to treat neutrophil-dependent 
diseases such as arthritis and infection-induced acute lung injury.
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